Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 7/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840987 | 1.00 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL13714694 | 1.00 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL13273469 | 0.81 | MEN1 (0.38) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL13273467 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL13273470 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL15519641 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL2574409 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL8673414 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL3015208 | 0.75 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTFNTA | |
| SCHEMBL7179918 | 0.72 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853542-B1 | PROCESS FOR THE PREPARATION OF CIS-2-ACETYL-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYLNAPHTHALENE | GIVAUDAN SA (CH) | 2015-07-15 | — | — | EP | claimed |
| US-7569732-B2 | Cyclisation process | GIVAUDAN SA (CH) | 2009-08-04 | — | — | US | claimed |
| US-20080114189-A1 | Cyclisation Process | GIVAUDAN SA (CH) | 2008-05-15 | — | — | US | claimed |
| EP-1853542-B1 | PROCESS FOR THE PREPARATION OF CIS-2-ACETYL-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYLNAPHTHALENE | GIVAUDAN SA (CH) | 2015-07-15 | — | — | EP | disclosed |
| CN-101124190-B | Process for the preparation of cis-2-acetyl-1, 2, 3, 4, 5, 6, 7, 8-octahydro-1, 2, 8, 8-tetramethylnaphthalene | GIVAUDAN SA | 2011-01-19 | — | — | CN | disclosed |
| EP-1656384-B1 | PROCESS FOR THE PREPARATION OF METHYLALUMINIUM DICHLORIDE | GIVAUDAN SA (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7569732-B2 | Cyclisation process | GIVAUDAN SA (CH) | 2009-08-04 | — | — | US | disclosed |
| US-7569732-B2 | Cyclisation process | GIVAUDAN SA (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20080114189-A1 | Cyclisation Process | GIVAUDAN SA (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114189-A1 | Cyclisation Process | GIVAUDAN SA (CH) | 2008-05-15 | — | — | US | disclosed |
| CN-101124190-A | Process for the preparation of cis-2-acetyl-1, 2, 3, 4, 5, 6, 7, 8-octahydro-1, 2, 8, 8-tetramethylnaphthalene | GIVAUDAN SA (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1853542-A1 | PROCESS FOR THE PREPARATION OF CIS-2-ACETYL-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYLNAPHTHALENE | Givaudan SA (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006086908-A1 | PROCESS FOR THE PREPARATION OF CIS-2-ACETYL-1, 2, 3, 4, 5, 6, 7, 8-OCTAHYDRO-1, 2, 8, 8-TETRAMETHYLNAPHTHALENE | GIVAUDAN SA (CH) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114189-A1 | Cyclisation Process | GGPS1, ECH1, ALG8 | MEN1 897/4885KMT2A 3486/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.